2023
DOI: 10.1016/j.preteyeres.2022.101115
|View full text |Cite
|
Sign up to set email alerts
|

Therapy with voretigene neparvovec. How to measure success?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
16
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(24 citation statements)
references
References 86 publications
0
16
0
Order By: Relevance
“…However, since then, other phase III trials on ocular gene therapy have failed to reach their primary endpoints, e.g., the XIRIUS study of an adeno-associated virus serotype 8 (AAV8) vector-based gene therapy, cotoretigene toliparvovec, targeting the RPGR gene in x-linked retinitis pigmentosa. One of the recurring key questions in all ophthalmological gene therapy studies therefore is: “How to measure success?” [23].…”
Section: Discussionmentioning
confidence: 99%
“…However, since then, other phase III trials on ocular gene therapy have failed to reach their primary endpoints, e.g., the XIRIUS study of an adeno-associated virus serotype 8 (AAV8) vector-based gene therapy, cotoretigene toliparvovec, targeting the RPGR gene in x-linked retinitis pigmentosa. One of the recurring key questions in all ophthalmological gene therapy studies therefore is: “How to measure success?” [23].…”
Section: Discussionmentioning
confidence: 99%
“…One of the recurring key questions in all ophthalmological gene therapy studies therefore is: "How to measure success?" [23]. This question underlines the complexity and importance of a reliable and objective measurement of visual performance for gene therapy studies in IRDs and beyond.…”
Section: Discussionmentioning
confidence: 99%
“…However, since then, other phase III trials on ocular gene therapy have failed to reach their primary endpoints, e.g., the XIRIUS study of an AAV serotype 8 (AAV8) vector-based gene therapy, cotoretigene toliparvovec, targeting the RPGR gene in X-linked retinitis pigmentosa. One of the recurring key questions in all ophthalmological gene therapy studies therefore is: “How to measure success?” 23 . This question underlines the complexity and importance of a reliable and objective measurement of visual performance for gene therapy studies in IRDs and beyond.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Morphological proof of the treatment effect is possible in some cases as well, although the most prominent proof of treatment effects remains the rod functional rescue. An interesting improvement in the area of retinal imaging of patients who underwent RPE65 gene therapy is the repeatedly reported improved signal of the fundus autofluorescence [29,36,37]. This contrasts with the enormous difficulties to obtain FAF images in the natural course of RPE65 retinal dystrophies and before treatment [22,37].…”
Section: Experiences With the Treatment Efficacymentioning
confidence: 99%